ArticlePharmaceutical research2002
An integrated pharmacodynamic analysis of erythropoietin, reticulocyte, and hemoglobin responses in acute anemia.
Article in Pharmaceutical research, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 31 citations in OpenAlex.
- An assessment of recombinant human erythropoietin effect on reticulocyte production rate and lifespan distribution in healthy subjects.Pharmaceutical research · 2007Trial
- A biomathematical model of human erythropoiesis under erythropoietin and chemotherapy administration.PloS one · 2013Article
- Receptor-based dosing optimization of erythropoietin in juvenile sheep after phlebotomy.Drug metabolism and disposition: the biological fate of chemicals · 2011Article
- Ribavirin-induced anemia in hepatitis C virus patients undergoing combination therapy.PLoS computational biology · 2011Article
- Quantitative analysis of mechanisms that govern red blood cell age structure and dynamics during anaemia.PLoS computational biology · 2009Article
- Modeling time variant distributions of cellular lifespans: increases in circulating reticulocyte lifespans following double phlebotomies in sheep.Journal of pharmacokinetics and pharmacodynamics · 2008Article
- Basic pharmacodynamic models for agents that alter the lifespan distribution of natural cells.Journal of pharmacokinetics and pharmacodynamics · 2008Article
- Increased erythropoietin elimination in fetal sheep following chronic phlebotomy.Pharmaceutical research · 2007Article
- Pharmacodynamic analysis of time-variant cellular disposition: reticulocyte disposition changes in phlebotomized sheep.Journal of pharmacokinetics and pharmacodynamics · 2007Article
- Pharmacodynamic model of interleukin-21 effects on red blood cells in cynomolgus monkeys.Journal of pharmacokinetics and pharmacodynamics · 2007Article
- A 'bottom-up' approach for endo-PK/PD analysis.Biopharmaceutics & drug disposition · 2006Article
- Pharmacodynamic models for agents that alter production of natural cells with various distributions of lifespans.Journal of pharmacokinetics and pharmacodynamics · 2006Article
- Pharmacodynamic analysis of changes in reticulocyte subtype distribution in phlebotomy-induced stress erythropoiesis.Journal of pharmacokinetics and pharmacodynamics · 2005Article
- Hypoxic stress tolerance of the blind subterranean mole rat: expression of erythropoietin and hypoxia-inducible factor 1 alpha.Proceedings of the National Academy of Sciences of the United States of America · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
purposeTo determine by pharmacodynamic (PD) analysis physiologically relevant parameters of the cellular kinetics of erythropoiesis in acute anemia.
methodsThe PD relationships among erythropoietin (EPO), reticulocyte, and RBC (Hb) responses were investigated in young adult sheep in acute anemia induced twice by two controlled phlebotomies separated by a 4-week recovery period.
resultsThe phlebotomies resulted in rapid increases in plasma EPO, with maximal levels occurring at 3 to 8 days, followed by a reticulocyte response with a delay of 0.5 to 1.5 days. The Hb returned to prephlebotomy base line at the end of the 4-week recovery period. The EPO, reticulocyte count, and Hb responses were well described by a PK/PD model (r = 0.975) with the following cellular kinetics parameters: the lag time between EPO activation of erythroid progenitor cells and reticulocyte formation; the reticulocyte-to-RBC maturation time; the reticulocyte and Hb formation efficacy coefficients, quantifying EPO's efficacy in stimulating the formation of reticulocytes and Hb, respectively; the C50 PK/PD transduction parameter defined as the EPO level resulting in half the maximum rate of erythropoiesis.
conclusionPhysiologically relevant cellular kinetics parameters can be obtained by an endogenous PK/PD analysis of phlebotomy data and are useful for elucidating the pathophysiologic etiology of various anemias.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.